enVVeno Medical Presents Three-Year Surgical Venous Valve Replacement Data Showing Sustained Clinical Benefit and Highlights Next-Generation enVVe Transcatheter System at the 53rd Annual VEITH Symposium
Key Highlights
- ➤VenoValve data shows a 5.8-point rVCSS improvement sustained through 36 months
- ➤VEINES-QOL improved 18 points and VEINES-Sym improved 19 points
- ➤enVVe transcatheter valve designed for same-day discharge under light sedation
- ➤TAVVE received FDA IDE authorization; first patient enrollment remains targeted by year-end 2026
Expert Statements
Robert Berman, Chief Executive Officer of enVVeno Medical
“Patients improved significantly after receiving the VenoValve, and this three-year data shows that those benefits have been sustained”
Robert Berman, Chief Executive Officer of enVVeno Medical
“Demonstrating the long-term viability of our replacement venous valve technology is critically important as we advance enVVe”
IRVINE, CA / ACCESS Newswire / November 20, 2026 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, will present three-year data from SAVVE, the U.S. pivotal study of the VenoValve(®) today at the 53rd Annual Vascular and Endovascular Issues, Techniques and Horizons (VEITH) Symposium in New York City. The data, which will be presented by Dr. David Dexter of Sentara Vascular Specialists, shows sustained, statistically significant improvements in the revised Venous Clinical Severity Score (rVCSS), leg pain and quality-of-life measures in patients with severe chronic venous insufficiency (CVI). The presentation will also highlight enVVe(®), the Company's next-generation, non-surgical transcatheter replacement venous valve. Among the data being presented at VEITH are: * 5.8-point average improvement in disease severity, as measured by rVCSS, from baseline to 36 months. * 18-point and 19-point average improvements in venous disease-specific quality of life (VEINES-QOL) and symptoms (VEINES-Sym), respectively. The rVCSS is a clinically validated scoring system used to track the progression or regression of venous diseases, and a 5.8-point improvement represents a real difference in the daily lives of these patients. Improvement was observed as early as three months following implantation and was sustained through 36 months.
Get started
Create a free account to read the full story.
